arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

TScan Therapeutics, Inc.

TCRX

$0.79 ▲ +0.03 (+3.39%) at close

7 Visible periods

30 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

TScan Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $102.5M

Dividend Yield —

Revenue Growth 266.7% ↗

Op. Margin None

ROIC -68.9% ↘

FCF / Share $-1.08 ↘

Trailing P/E —

Price / Book 0.8x

FCF Yield —

Debt / Equity 0.26

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$10.32M

↑ +266.7% —

Net Income Profit after all expenses

$-129.77M

↓ -1.8% —

Operating Margin Operating profit as % of sales

-444.0%

↑ +9.8% —

FCF / Share Free cash flow per share

$-1.08

↓ -5.2% —

Long-Term Debt Long-term obligations

$32.53M

↑ +1.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health →

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	266.7% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3233%)	-86.6% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1183%)	55.5% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+594%)	33.5% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+318%)	834.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+10333%)	—	—
EPS Growth YoY (%)	12.3% Fair ↓ Fair Declining Year-over-year change in earnings per share Optimal: > 10%	16.2% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	50.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	34.1% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-1.8% Weak ↑ Weak Improving Year-over-year change in net income	-42.9% Weak ↑ Weak Improving Year-over-year change in net income	-34.7% Weak ↑ Weak Improving Year-over-year change in net income	-36.2% Weak Weak Year-over-year change in net income	-86.1% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-5.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-4.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	66.6% Excellent Excellent Year-over-year change in free cash flow	41.5% Excellent Excellent Year-over-year change in free cash flow	—	—	—
Revenue CAGR 3Y (%)	-8.6% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-34.8% Weak Weak Compound annual revenue growth over 3 years	168.7% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	56.9% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	—	—	-444.0% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3060%)	-492.3% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3382%)	-479.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3298%)	—	—
Profit Margin (%) (%)	—	—	-423.9% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3632%)	-489.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4177%)	-479.5% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-4096%)	—	—
FCF Margin (%) (%)	—	—	-306.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	1.08x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair ↑ Fair Improving Free cash flow relative to reported net income Optimal: > 1x	1.21x Good Good Free cash flow relative to reported net income Optimal: > 1x	0.28x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-68.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-40.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-40.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-23.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	48.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-59.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-34.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-33.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-25.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-52.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-105.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-803%)	-52.9% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-453%)	-59.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-494%)	-66.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-544%)	-30.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-302%)	61.5% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+310%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	0.26x Excellent ↑ Excellent Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-56%)	0.13x Excellent ↓ Excellent Declining Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-78%)	0.20x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-67%)	0.29x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-51%)	—	—	—
Interest Coverage (x)	-49.05x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-36.91x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-24.86x Weak Weak Operating income divided by interest expense Optimal: > 5x	-56.66x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—
Net Debt (USD)	$-119.87M	$-146.62M	$-103.31M	$-90.74M	$-161.41M	$-34.79M	—
Debt / EBITDA (x)	-0.24x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.25x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.34x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.48x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.08	$0.03	$0.32	$0.56	$0.87	—	—
Basic EPS, GAAP (USD)	$-1.00	$-1.14	$-1.36	$-2.75	$-4.17	—	—
Free Cash Flow per Share (USD)	$-1.08	$-1.02	$-0.98	$-2.94	$-5.03	—	—
Book Value per Share (USD)	$0.95	$2.15	$2.30	$4.13	$13.79	—	—
Tangible Book Value per Share (USD)	$0.95	$2.15	$2.30	$4.13	$13.79	—	—
Basic Weighted Avg Shares (shares)	129.78M	111.99M	65.60M	24.05M	11.66M	—	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$138.51M	$256.77M	$164.42M	$106.82M	$144.31M	$19.00M	—
LT Debt (USD)	$32.53M	$32.07M	$30.05M	$29.29M	—	—	—
Total Equity (USD)	$123.12M	$240.97M	$150.87M	$99.43M	$160.78M	$-42.46M	$-17.14M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$10.32M	$2.82M	$21.05M	$13.54M	$10.14M	$1.08M	—
Depreciation Expense (USD)	$2.87M	$4.11M	$5.36M	$5.14M	$3.33M	$1.23M	—
Net Income, GAAP (USD)	$-129.77M	$-127.50M	$-89.22M	$-66.22M	$-48.62M	$-26.13M	—
Operating Cash Flow (USD)	$-135.32M	$-110.82M	$-61.36M	$-66.50M	$-48.68M	$-3.02M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

TScan Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare TCRX with peers